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E V I D E N C E - B A S E D A N S W E R
C L I N I C A L C O M M E N TA R Y
Immunization against encapsulated bacteri-
al pathogens decreases the incidence of
post-splenectomy sepsis. Pneumococcal,
meningococcal, and Haemophilus 
influenzae (Hib) vaccinations are indicated
for patients after splenectomy. These 
immunizations should be given at least 14
days before a scheduled splenectomy, or
given after the fourteenth postoperative day
(strength of recommendation [SOR]: A,
based on systematic review of RCTs for the
pneumococcal vaccine; SOR: B, based on
systematic review of clinical trials for
meningococcal and Hib vaccines).
Don’t forget those on prednisone,
immunosuppressants, or undergoing
chemotherapy
This is an important and often overlooked
component of preventive care—what to do
with an asplenic patient? Individuals with
functional asplenia from sickle-cell disease
or other causes should also probably be
included in this vaccination/revaccination
schedule.
Another patient group that may require a
more considered approach is those 
residing in long-term care facilities.
Attention to immunizations may be even
more important to a frail elder’s health in an
institutional setting: vaccinations historically
have been overlooked in this group,
and certainly revaccination could be even
more easily missed. I have occasionally 
discovered I was caring for an asplenic
patient in the nursing home upon reviewing
that patient’s medical history with a close
family member or caregiver.
Additionally, elders on chronic immuno-
suppressant therapy or prednisone for
rheumatoid arthritis or other autoimmune
disorders, and those on chemotherapy for
malignancies should also be revaccinated
with pneumococcal vaccine approximately
every 5 years.
David Cravens, MD
University of Missouri–Columbia
z Evidence summary
Asplenic individuals are known to be at an
elevated risk for infection with encapsulat-
ed bacteria. The lifetime risk of post-
splenectomy sepsis is estimated to be
approximately 1% to 2%. The overwhelm-
ing majority of these cases are caused by
Streptococcus pneumoniae, Haemophilus
influenzae, and Neisseria meningitides.1–4
In 2 recent RCTs, the 23-valent pneu-
mococcal polysaccharide vaccine was test-
ed on patients 1, 7, 14, and 28 days after
splenectomy.1,2 The studies demonstrated
that the immunogenicity of the vaccine
was best when given at or after day 14
after the operation. In both studies,
patients immunized at day 14 had
immunoglobulin G (IgG) antibody levels
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Those vaccinated
with Hib within 14
days (before or
after) splenectomy
had a significantly
higher need for
revaccination
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approaching those of control subjects with
intact spleens. There were no differences in
antibody levels among those patients
immunized at day 14 compared with those
immunized on day 28. However, those
subjects immunized on days 1 and 7 had
significant lower antibody levels than the
control subjects or those immunized on
day 14. 
In another study, 130 asplenic individ-
uals were compared with 48 age-matched
controls after receiving a meningococcal
vaccine.3 The majority (93%) achieved
bactericidal immunoglobulin levels follow-
ing immunization. This study demonstrat-
ed the need to have antibody titers drawn
to ensure immunization response, as 20%
of the subjects required a second dose of
vaccine to achieve adequate levels. No
clear evidence supports the timing of the
meningococcal vaccine post-splenectomy. 
Two recent studies look at the
immunogenicity of the Hib for asplenic
patients. The first study demonstrated
increased antibody titers to Hib at 2, 6, 12,
24, and 36 months after immunization.4
Fifty of the 57 patients in the study (88%)
maintained adequate antibody titers 3
years after immunization. No sympto-
matic infections were observed during the
3-year study period. In a study of 561
Danes, those vaccinated within 14 days of
splenectomy (before or after) had a signifi-
cantly higher need for revaccination than
those who were vaccinated more than 14
days before or after surgery.5
Recommendations from others
The most common infections occurring
among asplenic patients are due to
encapsulated organisms. The incidence is
10 to 50 times higher than in the general
population. 
The Advisory Committee on
Immunization Practices for the Centers for
Disease Control and Prevention (CDC)
and the Society of Surgery for the
Alimentary Tract recommends all patients
that undergo splenectomy have the pneu-
mococcal polysaccharide vaccine.6–7 In
addition, this organization also recom-
mends that all asplenic patients receive
meningococcal vaccination and be consid-
ered for the Hib vaccine. Both groups 
recommend that these vaccinations occur
at the same time as the pneumococcal 
vaccine.6–8
The CDC also recommends annual
influenza vaccine in addition to the pneu-
mococcal, meningococcal, and Hib 
vaccines, because secondary bacterial
infections can lead to severe disease in this
patient population. Boosters are recom-
mended for all the bacterial vaccines every
5 years for asplenic patients.
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